Skip to main content
Have a personal or library account? Click to login
Left Atrial Thrombus in the Setting of Mitral Stenosis Cover

Left Atrial Thrombus in the Setting of Mitral Stenosis

Open Access
|Aug 2023

Full Article

A 56-year-old man with no significant past medical history presented with exertional shortness of breath. On examination, vital signs were stable, and a mid-diastolic rumbling murmur was appreciated on auscultation. Electrocardiogram showed normal sinus rhythm with P mitrale. An echocardiogram (echo) showed a preserved ejection fraction, severe mitral stenosis, and a dilated left atrium with a large thrombus (5 × 3.8 cm). Cardiac magnetic resonance confirmed the echo findings with features consistent with a thrombus. Preoperative cardiac computed tomography showed that the thrombus originated from the left atrial appendage (Figure 1, Video 1). The patient underwent successful mitral valve replacement, left atrial thrombus resection, and left atrial appendage closure. Postoperatively, the patient’s shortness of breath significantly improved, and the follow-up echo showed a well-functioning mitral valve prosthesis.

Figure 1

Echocardiography and magnetic resonance imaging showing a thrombus in the left atrial appendage.

Video 1

Echocardiogram, cardiac magnetic resonance, and computed tomography show mitral stenosis and a left atrial thrombus; see also at https://youtu.be/lG5d5c3nBwg.

Left atrial thrombus formation is a well-known complication of severe mitral stenosis that can lead to systemic thromboembolism. It occurs secondary to the significant blood stasis in the dilated left atrium. To decrease the risk of thromboembolic complications, anticoagulation is recommended in patients with mitral stenosis complicated by atrial fibrillation. Moreover, in patients with significant mitral stenosis in sinus rhythm, long-term anticoagulation should be considered when the echo shows dense spontaneous echocardiographic contrast or an enlarged left atrium. A recent multicenter randomized study showed that vitamin K antagonist (VKA) therapy led to lower cardiovascular events compared with rivaroxaban therapy in patients with rheumatic heart disease-associated atrial fibrillation. Hence, VKA therapy is the recommended anticoagulation strategy in this population.1, 2, 3

Competing Interests

The authors have no competing interests to declare.

DOI: https://doi.org/10.14797/mdcvj.1272 | Journal eISSN: 1947-6108
Language: English
Page range: 61 - 63
Submitted on: Jun 25, 2023
Accepted on: Jul 26, 2023
Published on: Aug 24, 2023
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2023 Ola Abdelkarim, Yehia Saleh, Faisal Nabi, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.